A Study of IMC-TR1 in Participants With Advanced Solid Tumors

计划入组 14 人 · 首次发布于 2012 年 7 月 20 日

AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC

计划入组 24 人 · 首次发布于 2022 年 11 月 30 日

Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors

计划入组 22 人 · 首次发布于 2019 年 5 月 17 日

anti-PD1/TGFβ antibody (Jiangsu hengrui)

SON-3015

CD19/TGFβ CAR-T (Takeda Pharma)

Novel Anti-Infective Technologies, LLC

AiCuris Anti-Infective Cures AG

Germany

AGENCE REGIONALE DE SANTE DE LA REUNION

Reunion

NIH Awards $15.6 Million to Advance Research on Rare Bone and Metabolic Disorders

AdAPT-001, EpicentRx's Oncolytic Virus-Delivered TGFβ Inhibitor, Receives FDA Fast Track Designation for Soft Tissue Sarcoma

VasoRx's Lipid Nanoparticle Drug Delivery System Targets TGFβ-Related Diseases